Compare Dover Corp (DOV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Repligen Corporation Common Stock — how do they compare? Dover Corp trades at $193.04 (market cap $25.92B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Dover Corp is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and Dover Corp pays a 1.09% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 74 Days and Repligen Corporation Common Stock for 0 Days on average.
| DOV | RGEN | |
|---|---|---|
Market Cap | $25.92B | $11.14B |
Volume | 807,452 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $233.31 | $194.57 |
52-Week Low | $162.66 | $102.87 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $27.43B | $11.02B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $193.33, up 1.28% with strong analyst consensus of 19 Buy ratings and no Sell recommendations. The stock shows solid fundamentals with consistent earnings beats, 13.48% net margin, and robust cash flow. Recent acquisitions and product launches position the company for growth, while technical indicators suggest neutral momentum near key resistance at $195.
Outlook remains positive with 67.9% analyst Buy rating and $243.20 price target representing 26% upside. Risks include integration challenges from recent acquisitions and industrial sector volatility. The company's Dividend King status and strong balance sheet provide stability amid market fluctuations.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
